Wang et al9 showed that plasma IFNγ levels were significantly decreased in lung cancer patients and hypermethylation of the IFNγ promoter in CD4+ T cells was inversely associated with plasma IFNγ levels. The gene discussed is CD4; the disease is lung carcinoma.